2,490
Views
20
CrossRef citations to date
0
Altmetric
Invited Review

Non‐pharmaceutical treatment options for meibomian gland dysfunction

, MD PhD & , MD
Pages 742-755 | Received 29 May 2019, Accepted 19 Nov 2019, Published online: 15 Apr 2021

REFERENCES

  • Nichols KK, Foulks GN, Bron AJ et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci 2011; 52: 1922–1929.
  • Geerling G, Tauber J, Baudouin C et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2011; 52: 2050–2064.
  • Mcculley JP, Shine WE. Meibomian secretions in chronic blepharitis. Adv Exp Med Biol 1998; 438: 319–326.
  • Borchman D. The optimum temperature for the heat therapy for meibomian gland dysfunction. Ocul Surf 2019; 17: 360–364.
  • Lam SM, Tong L, Duan X et al. Longitudinal changes in tear fluid lipidome brought about by eyelid‐warming treatment in a cohort of meibomian gland dysfunction. J Lipid Res 2014; 55: 1959–1969.
  • Blackie CA, Solomon JD, Greiner JV et al. Inner eyelid surface temperature as a function of warm compress methodology. Optom Vis Sci 2008; 85: 675–683.
  • Solomon JD, Case CL, Greiner JV et al. Warm compress induced visual degradation and Fischer‐Schweitzer polygonal reflex. Optom Vis Sci 2007; 84: 580–587.
  • Bitton E, Lacroix Z, Leger S. In‐vivo heat retention comparison of eyelid warming masks. Cont Lens Anterior Eye 2016; 39: 311–315.
  • Murakami DK, Blackie CA, Korb DR. All warm compresses are not equally efficacious. Optom Vis Sci 2015; 92: e327–e333.
  • Bilkhu PS, Naroo SA, Wolffsohn JS. Randomised masked clinical trial of the MGDRx EyeBag for the treatment of meibomian gland dysfunction‐related evaporative dry eye. Br J Ophthalmol 2014; 98: 1707–1711.
  • Wang MT, Jaitley Z, Lord SM et al. Comparison of self‐applied heat therapy for meibomian gland dysfunction. Optom Vis Sci 2015; 92: e321–e326.
  • Wang MT, Gokul A, Craig JP. Temperature profiles of patient‐applied eyelid warming therapies. Cont Lens Anterior Eye 2015; 38: 430–434.
  • Arita R, Morishige N, Shirakawa R et al. Effects of eyelid warming devices on tear film parameters in Normal subjects and patients with Meibomian gland dysfunction. Ocul Surf 2015; 13: 321–330.
  • Purslow C. Evaluation of the ocular tolerance of a novel eyelid‐warming device used for meibomian gland dysfunction. Cont Lens Anterior Eye 2013; 36: 226–231.
  • Benitez del castillo JM, Kaercher T, Mansour K et al. Evaluation of the efficacy, safety, and acceptability of an eyelid warming device for the treatment of meibomian gland dysfunction. Clin Ophthalmol 2014; 8: 2019–2027.
  • Sim HS, Petznick A, Barbier S et al. A randomized, controlled treatment trial of eyelid‐warming therapies in meibomian gland dysfunction. Ophthalmol Ther 2014; 3: 37–48.
  • Villani E, Garoli E, Canton V et al. Evaluation of a novel eyelid‐warming device in meibomian gland dysfunction unresponsive to traditional warm compress treatment: an in vivo confocal study. Int Ophthalmol 2015; 35: 319–323.
  • Yeo S, Tan JH, Acharya UR et al. Longitudinal changes in tear evaporation rates after eyelid warming therapies in meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2016; 57: 1974–1981.
  • Turnbull PRK, Misra SL, Craig JP. Comparison of treatment effect across varying severities of meibomian gland dropout. Cont Lens Anterior Eye 2018; 41: 88–92.
  • Mori A, Shimazaki J, Shimmura S et al. Disposable eyelid‐warming device for the treatment of meibomian gland dysfunction. Jpn J Ophthalmol 2003; 47: 578–586.
  • Arita R, Morishige N, Sakamoto I et al. Effects of a warm compress containing menthol on the tear film in healthy subjects and dry eye patients. Sci Rep 2017; 7: 45848.
  • Goto E, Monden Y, Takano Y et al. Treatment of non‐inflamed obstructive meibomian gland dysfunction by an infrared warm compression device. Br J Ophthalmol 2002; 86: 1403–1407.
  • Paugh JR, Knapp LL, Martinson JR et al. Meibomian therapy in problematic contact lens wear. Optom Vis Sci 1990; 67: 803–806.
  • Sung J, Wang MTM, Lee SH et al. Randomized double‐masked trial of eyelid cleansing treatments for blepharitis. Ocul Surf 2018; 16: 77–83.
  • Tanabe H, Kaido M, Kawashima M et al. Effect of eyelid hygiene detergent on obstructive meibomian gland dysfunction. J Oleo Sci 2019; 68: 67–78.
  • Kaido M, Ibrahim OM, Kawashima M et al. Eyelid cleansing with ointment for obstructive meibomian gland dysfunction. Jpn J Ophthalmol 2017; 61: 124–130.
  • Guillon M, Maissa C, Wong S. Eyelid margin modification associated with eyelid hygiene in anterior blepharitis and meibomian gland dysfunction. Eye Contact Lens 2012; 38: 319–325.
  • Tanabe H, Kawashima M, Kaido M et al. Safety and efficacy of wiping lid margins with lid hygiene shampoo using the "eye brush", a novel lid hygiene item, in healthy subjects: a pilot study. BMC Ophthalmol 2019; 19: 41.
  • Liu J, Sheha H, Tseng SC. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol 2010; 10: 505–510.
  • Zhang XB, Ding YH, He W. The association between demodex infestation and ocular surface manifestations in meibomian gland dysfunction. Int J Ophthalmol 2018; 11: 589–592.
  • Liang L, Liu Y, Ding X et al. Significant correlation between meibomian gland dysfunction and keratitis in young patients with Demodex brevis infestation. Br J Ophthalmol 2018; 102: 1098–1102.
  • Fromstein SR, Harthan JS, Patel J et al. Demodex blepharitis: clinical perspectives. Clin Optom (Auckl) 2018; 10: 57–63.
  • English FP, Nutting WB. Demodicosis of ophthalmic concern. Am J Ophthalmol 1981; 91: 362–372.
  • Luo X, Li J, Chen C et al. Ocular demodicosis as a potential cause of ocular surface inflammation. Cornea 2017; 36: S9–S14.
  • Rabensteiner DF, Aminfar H, Boldin I et al. Demodex mite infestation and its associations with tear film and ocular surface parameters in patients with ocular discomfort. Am J Ophthalmol 2019; 204: 7–12.
  • Lacey N, Ni raghallaigh S, Powell FC. Demodex mites ‐ commensals, parasites or mutualistic organisms? Dermatology 2011; 222: 128–130.
  • Kligman AM, Christensen MS. Demodex folliculorum: requirements for understanding its role in human skin disease. J Invest Dermatol 2011; 131: 8–10.
  • Pena GP, Andrade filho JS. Is demodex really non‐pathogenic? Rev Inst Med Trop Sao Paulo 2000; 42: 171–173.
  • Gao YY, Di pascuale MA, Elizondo A et al. Clinical treatment of ocular demodecosis by lid scrub with tea tree oil. Cornea 2007; 26: 136–143.
  • Halcon L, Milkus K. Staphylococcus aureus and wounds: a review of tea tree oil as a promising antimicrobial. Am J Infect Control 2004; 32: 402–408.
  • Hammer KA, Carson CF, Riley TV. Antifungal effects of Melaleuca alternifolia (tea tree) oil and its components on Candida albicans, Candida glabrata and Saccharomyces cerevisiae. J Antimicrob Chemother 2004; 53: 1081–1085.
  • Caldefie‐chezet F, Guerry M, Chalchat JC et al. Anti‐inflammatory effects of Melaleuca alternifolia essential oil on human polymorphonuclear neutrophils and monocytes. Free Radic Res 2004; 38: 805–811.
  • Gao YY, Di pascuale MA, Li W et al. In vitro and in vivo killing of ocular Demodex by tea tree oil. Br J Ophthalmol 2005; 89: 1468–1473.
  • Tighe S, Gao YY, Tseng SC. Terpinen‐4‐ol is the most active ingredient of tea tree oil to kill Demodex mites. Transl Vis Sci Technol 2013; 2: 2.
  • Koo H, Kim TH, Kim KW et al. Ocular surface discomfort and Demodex: effect of tea tree oil eyelid scrub in Demodex blepharitis. J Korean Med Sci 2012; 27: 1574–1579.
  • Mcculley JP, Sciallis GF. Meibomian keratoconjunctivitis. Am J Ophthalmol 1977; 84: 788–793.
  • Hom MM, Silverman MW. Displacement technique and meibomian gland expression. J Am Optom Assoc 1987; 58: 223–226.
  • Keith CG. Seborrhoeic blepharo‐kerato‐conjinctivitis. Trans Ophthalmol Soc U K 1967; 87: 85–103.
  • Gifford S. Meibomian glands in chronic blepharo‐conjunctivitis. Am J Ophthalmol 1921; 4: 489–494.
  • Korb DR, Blackie CA. Meibomian gland therapeutic expression: quantifying the applied pressure and the limitation of resulting pain. Eye Contact Lens 2011; 37: 298–301.
  • Lee H, Kim M, Park SY et al. Mechanical meibomian gland squeezing combined with eyelid scrubs and warm compresses for the treatment of meibomian gland dysfunction. Clin Exp Optom 2017; 100: 598–602.
  • Aketa N, Shinzawa M, Kawashima M et al. Efficacy of plate expression of meibum on tear function and ocular surface findings in meibomian gland disease. Eye Contact Lens 2019; 45: 19–22.
  • Wang DH, Liu XQ, Hao XJ et al. Effect of the meibomian gland squeezer for treatment of meibomian gland dysfunction. Cornea 2018; 37: 1270–1278.
  • Maskin SL. Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction. Cornea 2010; 29: 1145–1152.
  • Wladis EJ. Intraductal meibomian gland probing in the management of ocular rosacea. Ophthalmic Plast Reconstr Surg 2012; 28: 416–418.
  • Nakayama N, Kawashima M, Kaido M et al. Analysis of meibum before and after intraductal meibomian gland probing in eyes with obstructive meibomian gland dysfunction. Cornea 2015; 34: 1206–1208.
  • Ma X, Lu Y. Efficacy of intraductal meibomian gland probing on tear function in patients with obstructive meibomian gland dysfunction. Cornea 2016; 35: 725–730.
  • Sik sarman Z, Cucen B, Yuksel N et al. Effectiveness of intraductal meibomian gland probing for obstructive meibomian gland dysfunction. Cornea 2016; 35: 721–724.
  • Syed ZA, Sutula FC. Dynamic intraductal meibomian probing: a modified approach to the treatment of obstructive meibomian gland dysfunction. Ophthalmic Plast Reconstr Surg 2017; 33: 307–309.
  • Incekalan TK, Harbiyeli II, Yagmur M et al. Effectiveness of intraductal meibomian gland probing in addition to the conventional treatment in patients with obstructive meibomian gland dysfunction. Ocul Immunol Inflamm 2019; 27: 1345–1351.
  • Maskin SL, Testa WR. Growth of meibomian gland tissue after intraductal meibomian gland probing in patients with obstructive meibomian gland dysfunction. Br J Ophthalmol 2018; 102: 59–68.
  • Arita R, Itoh K, Maeda S et al. A newly developed noninvasive and mobile pen‐shaped meibography system. Cornea 2013; 32: 242–247.
  • Korb DR, Blackie CA. Restoration of meibomian gland functionality with novel thermodynamic treatment device‐a case report. Cornea 2010; 29: 930–933.
  • Lane SS, Dubiner HB, Epstein RJ et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea 2012; 31: 396–404.
  • Korb DR, Blackie CA. Case report: a successful LipiFlow treatment of a single case of meibomian gland dysfunction and dropout. Eye Contact Lens 2013; 39: e1–e3.
  • Kenrick CJ, Alloo SS. The limitation of applying heat to the external lid surface: a case of recalcitrant meibomian gland dysfunction. Case Rep Ophthalmol 2017; 8: 7–12.
  • Finis D, Hayajneh J, Konig C et al. Evaluation of an automated thermodynamic treatment (LipiFlow(R)) system for meibomian gland dysfunction: a prospective, randomized, observer‐masked trial. Ocul Surf 2014; 12: 146–154.
  • Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single‐dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol 2016; 10: 1385–1396.
  • Zhao Y, Veerappan A, Yeo S et al. Clinical trial of thermal pulsation (LipiFlow) in Meibomian gland dysfunction with Preteatment Meibography. Eye Contact Lens 2016; 42: 339–346.
  • Zhao Y, Xie J, Li J et al. Evaluation of monocular treatment for meibomian gland dysfunction with an automated thermodynamic system in elderly Chinese patients: a contralateral eye study. J Ophthalmol 2016; 2016: 9640643.
  • Epitropoulos AT, Goslin K, Bedi R et al. Meibomian gland dysfunction patients with novel Sjogren's syndrome biomarkers benefit significantly from a single vectored thermal pulsation procedure: a retrospective analysis. Clin Ophthalmol 2017; 11: 701–706.
  • Hagen KB, Bedi R, Blackie CA et al. Comparison of a single‐dose vectored thermal pulsation procedure with a 3‐month course of daily oral doxycycline for moderate‐to‐severe meibomian gland dysfunction. Clin Ophthalmol 2018; 12: 161–168.
  • Greiner JV. A single LipiFlow(R) thermal pulsation system treatment improves meibomian gland function and reduces dry eye symptoms for 9 months. Curr Eye Res 2012; 37: 272–278.
  • Greiner JV. Long‐term (12‐month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment. Clin Experiment Ophthalmol 2013; 41: 524–530.
  • Finis D, Konig C, Hayajneh J et al. Six‐month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy. Cornea 2014; 33: 1265–1270.
  • Satjawatcharaphong P, Ge S, Lin MC. Clinical outcomes associated with thermal pulsation system treatment. Optom Vis Sci 2015; 92: e334–e341.
  • Greiner JV. Long‐term (3 year) effects of a single thermal pulsation system treatment on meibomian gland function and dry eye symptoms. Eye Contact Lens 2016; 42: 99–107.
  • Papageorgiou P, Clayton W, Norwood S et al. Treatment of rosacea with intense pulsed light: significant improvement and long‐lasting results. Br J Dermatol 2008; 159: 628–632.
  • Toyos R, Mcgill W, Briscoe D. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3‐year retrospective study. Photomed Laser Surg 2015; 33: 41–46.
  • Craig JP, Chen YH, Turnbull PR. Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2015; 56: 1965–1970.
  • Gupta PK, Vora GK, Matossian C et al. Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. Can J Ophthalmol 2016; 51: 249–253.
  • Vegunta S, Patel D, Shen JF. Combination therapy of intense pulsed light therapy and meibomian gland expression (IPL/MGX) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis. Cornea 2016; 35: 318–322.
  • Jiang X, Lv H, Song H et al. Evaluation of the safety and effectiveness of intense pulsed light in the treatment of meibomian gland dysfunction. J Ophthalmol 2016; 2016: 1910694.
  • Dell SJ, Gaster RN, Barbarino SC et al. Prospective evaluation of intense pulsed light and meibomian gland expression efficacy on relieving signs and symptoms of dry eye disease due to meibomian gland dysfunction. Clin Ophthalmol 2017; 11: 817–827.
  • Liu R, Rong B, Tu P et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. Am J Ophthalmol 2017; 183: 81–90.
  • Albietz JM, Schmid KL. Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction. Clin Exp Optom 2018; 101: 23–33.
  • Rong B, Tang Y, Tu P et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomed Laser Surg 2018; 36: 326–332.
  • Rong B, Tang Y, Liu R et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomed Laser Surg 2018; 36: 562–567.
  • Arita R, Mizoguchi T, Fukuoka S et al. Multicenter study of intense pulsed light therapy for patients with refractory meibomian gland dysfunction. Cornea 2018; 37: 1566–1571.
  • Arita R, Fukuoka S, Morishige N. Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocul Surf 2019; 17: 104–110.
  • Seo KY, Kang SM, Ha DY et al. Long‐term effects of intense pulsed light treatment on the ocular surface in patients with rosacea‐associated meibomian gland dysfunction. Cont Lens Anterior Eye 2018; 41: 430–435.
  • Ahmed SA, Taher IME, Ghoneim DF et al. Effect of intense pulsed light therapy on tear proteins and lipids in meibomian gland dysfunction. J Ophthalmic Vis Res 2019; 14: 3–10.